“It is vital to identify patients who are at a high risk for ACS after TAVR for potential treatment beforehand,” according a new analysis published in the American Journal of Cardiology.

Patients with pure native AR are often excluded from clinical trials comparing TAVR and SAVR, leading to a lack of clarity when it comes to the proper treatment of this population.

Many patients still require a permanent pacemaker following TAVR. In fact, it is more common after TAVR than after surgical aortic valve replacement. 

The new Boston Scientific valve received CE mark approval in 2020, but has not been approved by the FDA.

Commissural alignment is especially important now, researchers explained, because TAVR is being recommended for younger patients with longer life expectancies. 

According to a new study of more than 119,000 hospitalizations, the costs associated with TAVR are far from consistent. 

A team of specialists examined new outcomes data related to the SAPIEN 3 Ultra transcatheter heart valve, sharing its findings in EuroIntervention.

Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.